- Home
- ZENV vs CNTB Comparison
ZENV vs CNTB Comparison
Compare ZENV & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- CNTB
- Stock Information
- Founded
- ZENV 2005
- CNTB 2012
- Country
- ZENV Brazil
- CNTB United States
- Employees
- ZENV N/A
- CNTB N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- CNTB Health Care
- Exchange
- ZENV Nasdaq
- CNTB Nasdaq
- Market Cap
- ZENV 79.7M
- CNTB 90.3M
- IPO Year
- ZENV 2021
- CNTB 2021
- Fundamental
- Price
- ZENV $1.43
- CNTB N/A
- Analyst Decision
- ZENV
- CNTB Strong Buy
- Analyst Count
- ZENV 0
- CNTB 2
- Target Price
- ZENV N/A
- CNTB $7.50
- AVG Volume (30 Days)
- ZENV 104.7K
- CNTB 88.0K
- Earning Date
- ZENV 11-17-2025
- CNTB 11-13-2025
- Dividend Yield
- ZENV N/A
- CNTB N/A
- EPS Growth
- ZENV N/A
- CNTB N/A
- EPS
- ZENV N/A
- CNTB N/A
- Revenue
- ZENV $201,426,369.00
- CNTB $1,965,000.00
- Revenue This Year
- ZENV $6.49
- CNTB N/A
- Revenue Next Year
- ZENV $3.82
- CNTB $453,067.90
- P/E Ratio
- ZENV N/A
- CNTB N/A
- Revenue Growth
- ZENV 24.80
- CNTB N/A
- 52 Week Low
- ZENV $1.02
- CNTB $1.23
- 52 Week High
- ZENV $3.03
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- ZENV 54.00
- CNTB 58.99
- Support Level
- ZENV $1.26
- CNTB $1.36
- Resistance Level
- ZENV $1.48
- CNTB $1.88
- Average True Range (ATR)
- ZENV 0.08
- CNTB 0.15
- MACD
- ZENV 0.02
- CNTB 0.04
- Stochastic Oscillator
- ZENV 90.91
- CNTB 99.48
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.